SOUTH SAN FRANCISCO, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) will announce an encouraging development in the Zingo(TM) development program before the markets open tomorrow. A conference call and live webcast will be held at 8:30 a.m. Eastern Time tomorrow to discuss the announcement.
Interested parties can listen to the live audio webcast by dialing 800-340-6289 (international dial: 706-634-1538) or by logging on to http://www.anesiva.com and going to the Investor Information page. Please connect to Anesiva's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. For those unable to participate via the Internet, a 24-hour replay will be available for seven days after the call by dialing 800-642-1687 (international dial: 706-645-9291) and giving the following pass code: 13882358.
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has two drug candidates in development for multiple pain-related indications. A New Drug Application (NDA) has been filed for the most advanced product, Zingo(TM). The second product in the pipeline, Adlea(TM) (formerly 4975), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.
|SOURCE Anesiva, Inc.|
Copyright©2007 PR Newswire.